UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS . P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/632,108	,108 08/01/2003 Tsuyoshi Yuki		103176-00003	3473
4372 ARENT FOX I	7590 05/14/200 PLLC	7	EXAM	IINER
1050 CONNEC	CTICUT AVENUE, N.	W.	GOLOBOY	, JAMES C
SUITE 400 WASHINGTO	N, DC 20036		ART UNIT	PAPER NUMBER
	•	,	1714	
			MAIL DATE	DELIVERY MODE
			05/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

			('
		Application No.	Applicant(s)
	Office A - 41 - 11 October 1991	10/632,108	YUKI ET AL.
	Office Action Summary	Examiner	Art Unit
		James Goloboy	1714
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the o	correspondence address
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir- vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).
Status			
1)	Responsive to communication(s) filed on 23 Fe	ebruary 2007.	
·	-	action is non-final.	
3)□	Since this application is in condition for allowar	nce except for formal matters, pro	osecution as to the merits is
•	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.
Dispositi	ion of Claims		
4)🛛	Claim(s) <u>1-5,7-12 and 14-23</u> is/are pending in t	he application.	
	4a) Of the above claim(s) is/are withdrav	vn from consideration.	
5)	Claim(s) is/are allowed.		*
	Claim(s) <u>1-5,7-12 and 14-23</u> is/are rejected.		*
· · · · · · · · · · · · · · · · · · ·	Claim(s) <u>5</u> is/are objected to.		
8)[_]	Claim(s) are subject to restriction and/or	r election requirement.	
Applicati	on Papers		
9)[The specification is objected to by the Examine	r.	
10)	The drawing(s) filed on is/are: a) acce	epted or b) objected to by the	Examiner.
	Applicant may not request that any objection to the		• •
44)	Replacement drawing sheet(s) including the correcti		
11)[]	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.
Priority u	ınder 35 U.S.C. § 119		
_	Acknowledgment is made of a claim for foreign All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)-(d) or (f).
-/1	1. Certified copies of the priority documents	s have been received.	
	2. Certified copies of the priority documents		ion No
	3. Copies of the certified copies of the prior	ity documents have been receive	ed in this National Stage
	application from the International Bureau	(PCT Rule 17.2(a)).	
* 8	See the attached detailed Office action for a list of	of the certified copies not receive	ed.
			•
Attachmen	• •	•	
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔲 Interview Summäry Paper No(s)/Mail Da	
3) Inform	mation Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal P	
Pape	r No(s)/Mail Date	6) Other:	

Art Unit: 1714

DETAILED ACTION

1. Please note the new examiner of record.

2. All outstanding rejections have been overcome by applicant's amendments of 2/23/07. New grounds of rejection necessitated by the amendments are set forth below.

Claim Objections

3. Claim 5 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 5 requires the branched alkyl R group of claim 1 to contain 20-24 carbon atoms. However, amended claim 1 already contains the same requirement.

Claim Rejections - 35 USC § 103

4. Claims 1-5, 7-12, and 14-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yuki (U.S. Pat. No. 6,746,993, "Yuki '993").

Yuki '993 is a continuation-in-part of application 10/114,283, which was published as PG Pub No. 2003/0036488 ("Yuki '488"). Subject matter in Yuki '993 which finds support in Yuki '488 is therefore accorded the earlier date of April 3, 2002. In Table 1 of Yuki '993, polymers made from a mixture comprising

Art Unit: 1714

various methacrylate monomers are disclosed:

TABLE 1

Example No.	Мосотел	D m	ADVN	Tohiese	Polyme:	
	Kied	wdę		pow	wdę	No.
1	DTM/MM/HM/DMAEM	32/36/30/2	0.9	0.5	25	A-1
2	DDHM/MM/DDM/HM	20/36/32/12	0.9	0.5	25	A-2
3	DTE, M/MM/DDM/HM	20/32/38/10	0.9	0.5	25	A-3
4	DTM/MM/HM	30/38/32	0.9	0.5	25	A-4
5	DDHM/MM/DDM/HM	20/35/30/12	0.9	0.5	25	A-5
6	DTM/MM/DDM	20/30/50	0.9	0.5	25	A-6
7	DTM/DDHM/MM/DDM/DEAEM	30/10/35/23/2	0.9	0.5	25	A-7
8	DTM/MM/HM	30/35/35	0.9	0.5	25	A-8
9	MM/DDM/HM	20/70/10	0.9	0.5	25	ΑÐ
10	OM/DDM	20/80	E.0	0.4	25	B-1
11	EHM/DDM/DMAEM	48/50/2	6.9	0.5	25	B-2
12	MM/DDM	55/45	0.0	0.5	25	B-3
13	DSM/MM/HM	40/30/30	0.9	0.5	25	B-4
14	MM/OX, M/OX, M/HM/OM	30/25/25/14/6	1.0	0.47	17.6	A-10
15	MM/DDM/TM/HM/OM	30/35/15/14/6	1.0	0.47	17.6	A-11
16	MM/DDM/TM/HM/OM/DSM	26/40/20/7/3/2	1.0	0.47	17.6	A-12

Tables 1-2 of Yuki '488 disclose similar polymers:

Art Unit: 1714

TABLE 1

		Tt (* C.) cf
	Monomer	homopolyme
s.1-I	2-decyl-mindecyl methocylsis	-30
a1-2	2-dodocyf-hexadecyl methacrylain	-14
a1-3	2-decyl-tetradecyfoxyethyl metheoryfate	-25
3-1	2-cthylhexyl methacrylate	<=40 (*1)
<u>ي</u> ٠.۲	a-decopy! methodylate	45

(*1) lass than -40° C.

TABLE 2

		Copoly-	Monomer								D	AD			
			sJ-1	s1-2	s1-3	s3 -1	a5-1	12-1	# 4-1	84-2	s3-2	41	d-2	М	VN
Example	`1	A-1	32					35	30	• • • • • • • • • • • • • • • • • • • •		2		0.9	0.5
	2	A-2		20				35	12		32			0.9	g. <i>5</i>
	3	A-3			20			32	10		38			0.9	0.5
	4	Ar4	30					39	32					0.9	0.5
	5	A-S		20				38	12		30			0.9	0.5
	ó	À-6	20					30			50			0.9	0,5
	7	A-7	30	10				35			23		2	0.9	0.5
	8	BAA	3D					35	35					D.3	0.5
	g.	وسم .						20	10		70			0.9	0.5
	51	B-1								20	80			0.3	0,4
C. Example	1	X-1				48					59	2		0.9	0.5
	2	X-2						55			45			0.9	0.5
	3	X-3			·		40	33	30					0.9	0.5

e2-1: methyl metherrysie

In fact, polymers A-1 through A-9, and B-1 of Yuki '993 and Yuki '488 are identical. For example, polymer A-1 of both references is formed from a monomer mixture comprising 32% by weight of 2-decyl-tetradecyl methacrylate (DTM), 36% by weight of methyl methacrylate (MM), 30% by weight of n-hexadecyl methacrylate (HM), and 2% by weight of N,N-dimethyl aminoethylmethacrylate (DMAEM).

Yuki '993 teaches in column 7 lines 21-65 that the monomer mixture may further comprise an unsaturated monomer containing a hydroxyl or carboxyl group, which is also taught in paragraphs 76-91 of Yuki '488.

a4-1: z-hexadecyl meižacrylate

a4-2: a-octadecyl methacrylate

s3-2: a-dodacy) methacrylate

d-1: N,N-dimethyl amincethyl methacrylate

d-2: N,N-diethyl amino ethyl methacrylate

Art Unit: 1714

Yuki '993 teaches in column 4 lines 14-17 and column 8 lines 39-40 that the composition can further contain 10-60% by weight of a C₁₋₄ alkyl (meth)acrylate, which is mirrored in paragraphs 40 and 95 of Yuki '488. Examples 17-29 of Yuki '993 (Columns 17-18 and Table 3-4) disclose concentrates and lubricating compositions of the copolymer, which are supported by paragraphs 173-178 and Table 3-4 of Yuki '488. In column 13 lines 10-15 of Yuki '993, supported by paragraph 126 of Yuki '488, the uses of lubricating compositions recited in claim 21 are disclosed.

The above subject matter is therefore properly accorded a date of April 3, 2002, and qualifies as prior art.

Example 8 (Polymer A-8) of Yuki '993 is formed from a monomer mixture comprising 30% by weight of DTM (24 carbons), meeting the limitations of monomer (a) of claims 1, 5, 8, and 15, and 35% by weight of HM (16 carbons), meeting the limitations of monomer (b) of claims 1 and 15. The difference between polymer A-8 and the polymer of claim 1 is that copolymer A-8 does not contain an unsaturated monomer having a hydroxyl and/or carboxyl group.

As discussed above, Yuki '993 teaches in column 7 lines 21-65 that the monomer mixture may further comprise an unsaturated monomer containing a hydroxyl or carboxyl group, as recited in claims 1(c) and 9, and recited specific monomers meeting the limitations of claims 10-12 and 14. In column 9 lines 31-32, Yuki '993 teaches that this monomer is used in an amount of 0-20%, particularly 0.1-10%, overlapping the range recited in claim 1(c), and matching the 10% endpoint of claim 15. See MPEP 2144.05(I): "In the case where the

Art Unit: 1714

claimed ranges "overlap or lie inside ranges disclosed by the prior art" a *prima* facie case of obviousness exists. *In re Wertheim*, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). In light of the above, claims 1, 5, 8-12, and 14-15 are rendered obvious by Yuki '993.

Additionally, the use of DTM meets the limitations of claims 2-4 where p is 1, R' is a straight-chain alkyl group containing 12 carbon atoms, and R'' is a straight-chain alkyl group containing 10 carbon atoms.

Yuki '993 teaches in column 4 lines 14-17 and column 8 lines 39-40 that the composition can further contain 10-60% by weight of a C₁₋₄ alkyl (meth)acrylate, where the 10% endpoint matches the endpoint recited in claim 16, and overlaps the range of up to 15% recited in claim 7. Examples 17-29 of Yuki '993 (Columns 17-18 and Table 3-4) disclose concentrates and lubricating compositions of the copolymer, comprising 24 and 17% by weight respectively of the copolymer, and where the base oil has a kinematic viscosity of 3 mm²/s and a viscosity index of 117, meeting the limitations of claims 17-20. In column 13 lines 10-15 of Yuki '993, the uses of the lubricating compositions recited in claim 21 are disclosed.

While Yuki '993 does not explicitly disclose a copolymer having the solubility parameters recited in claims 22-23, it is the examiner's position that as all the structural features of the copolymer are rendered obvious, the solubility parameters would have been inherent.

Application/Control Number: 10/632,108 Page 7

Art Unit: 1714

Response to Arguments

As a prima facie case of obviousness has been set forth in paragraph 4 above, it is appropriate to consider the Rule 132 declarations filed by applicant dated 8/31/06 and 12/6/06. The 8/31/06 declaration compares compositions comprising a copolymer prepared from a monomer mixture comprising an unsaturated monomer containing a least one of a hydroxyl or carboxyl group with compositions that do not contain such a monomer, and the 12/6/06 declaration compares compositions comprising a copolymer prepared from a monomer mixture comprising 4% by weight of the unsaturated monomer described above with copolymers prepared from mixtures comprising 6% and 25% by weight of the unsaturated monomer.

The data presented in these declarations is incommensurate with the scope of the claims. Specifically, the only unsaturated monomers used in the compositions that demonstrate alleged superior performance are hydroxyethyl methacrylate and methacrylic acid, while claim 1 recites *any* unsaturated monomer containing at least one hydroxyl or carboxyl group. The dependent claims, while narrower, still include other monomers that are not present in the compositions examined in the declarations. Additionally, claim 16 allows for the monomer mixture to comprise up to 10% by weight of a C₁₋₄ alkyl (meth)acrylate, such as methyl methacrylate, but in the declaration of 8/31/06 such a monomer is only present in the compositions that exhibit alleged inferior performance.

Conclusion

Art Unit: 1714

5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Goloboy whose telephone number is 571-272-2476. The examiner can normally be reached on M-F 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vasu Jagannathan can be reached on 571-272-1119. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1714

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jewis C. Colday JCG VASU JAGANNATHAN
VASU JAGANNATHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1700